Gene therapy strategies for novel cancer therapeutics

Current Opinion in Oncology

Volumn 8, Issue 1, 1996, Pages 72-77

  Rosenfeld, Maryland E ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; CARBOXYPEPTIDASE G2; COLONY STIMULATING FACTOR 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOCHROME P450 ISOENZYME; CYTOKINE; CYTOSINE DEAMINASE; GANCICLOVIR; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; PLASMID DNA; PROTEIN P53; PURINE NUCLEOSIDE PHOSPHORYLASE; RIBOZYME; SOMATOMEDIN C RECEPTOR; THYMIDINE KINASE; TOXIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

CANCER THERAPY; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOPOTENTIATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0029945583     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199601000-00013     Document Type: Review

References (73)

1. Whartenby KA, Abboud CN, Marrogi AJ, Ramesh R, Freeman SM: Biology of disease: the biology of cancer gene therapy. Lab Invest 1995, 72:131-145.
2. O'Brien SG, Kirkland MA, Goldman JM: Antisense therapy for malignant disease. Eur J Cancer 1994, 30A:1160-1164.
3. Sullivan SM: Development of ribozymes for gene therapy. J Invest Dermatol 1994, 103:85S-89S.
4. Marasco W: Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology 1995, 1:1-19. This review provides a comprehensive update on the use of intracellular antibodies with the focus on gene therapy for HIV and cancer.
5. Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Helene C, Saison-Behmoaras T: Antisense oligonucleotides absorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci U S A 1994, 91:10460-10464.
6. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS: Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 1995, 92:3318-3322.
7. Laird AD, Brown PI, Fausto N: Inhibition of tumor growth in liver epithelial cells transfected with a transforming growth factor α antisense gene. Cancer Res 1994, 54: 4224-4232.
8. Dosaka-Akita H, Akie K, Hiroumi H, Kinoshita I, Kawakami Y, Murakami A: Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res 1995, 55:1559-1564.
9. Singh P, Dai B, Dhruva B, Widen SG: Episomal expression of sense and antisense insulin-like growth factor (IGF)-blnding protein-4 complementary DNA alters the mltogenlc response of a human colon cancer cell line (HT-29) by mechanisms that are independent of and dependent upon IGF-1. Cancer Res 1994, 54:6563-6570.
10. Shapiro DN, Jones BG, Shapiro LH, Dias P, Houghton PJ: Antisense-mediated reduction in insulin-like growth factor-1 receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 1994, 94:1235-1242.
11. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994, 54:4848-4850.
12. Long L, Rubin R, Baserga R, Brodt P: Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995, 55:1006-1009.
13. Gardner HAR, Berse B, Senger DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 1994, 9:2321-2326.
14. Nesterova M, Cho-Chung YS: A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nat Med 1995, 1:528-533.
15. Lu D, Chatterjee S, Brar D, Wong KK Jr: Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human Papillomavirus type 16. Cancer Gene Ther 1994, 1:267-277.
16. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy EP: Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 1995, 85:2162-2170.
17. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995, 55:2024-2028. Use of a recombinant adenoviral vector to efficiently deliver a H-RAS ribozyme was reported to revert the neoplastic phenotype in mutant H-RAS-expressing cells.
18. Sheppard D: Dominant negative mutants: tools for the study of protein function in vitro and in vivo. Am J Respir Cell Mol Biol 1994, 11:1-6. This review covers recent strategies for studying protein function based on dominant negative mutants. It provides a comprehensive overview and includes a variety of clinically relevant examples.
19. Claffey KP, Senger DR, Spiegelman BM: Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim Biophys Acta 1995, 1246:1-9.
20. Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N: Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Ther 1994, 1:403-407.
21. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT: Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1994, 1:332-337. An intracellular single-chain antibody, targeted to the endoplasmic reticulum was directed against the erbB-2 oncogene.
22. Beerli RR, Weis W, Hynes NE: Intracellular expression of single chain antibodies reverts erbB-2 transformation. J Biol Chem 1994, 269:23931-23936.
23. Beerli RR, Wels W, Hynes NE: Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Commun 1994, 2:666-672.
24. Bejcek BE, Wang D, Berven E, Pennell CA, Peiper SC, Poppema S, Uckun FM, Kersey JH: Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res 1995, 55:2346-2351.
25. Richardson JH, Sodroski JG, Waldman TA, Marasco WA: Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the a subunit of the receptor. Proc Natl Acad Sci U S A 1995, 92:3137-3141.
26. Roth JA, Mukhopadhyay T, Zhang WW, Fujiwara T, Georges R: Gene replacement strategies for the prevention and therapy of cancer. Eur J Cancer 1994, 30A:2032-2037.
27. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994, 86:1458-1462. This paper demonstrates that direct administration of a retroviral vector-expressing wild-type p53 may inhibit local growth of human lung cancer cells that are deficient in wild-type p53.
28. Clayman GL, El-Naggar AK, Roth JA, Zhang W-W, Goepfert H, Taylor DL, Liu T-J: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995, 55:1-6.
29. RB, the retinoblastoma tumor suppressor protein. Oncogene 1995, 10:697-704.
30. Hsieh J-T, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin S-H: Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (E-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 1995, 55:190-197.
31. Groden J, Joslyn G, Samowitz W, Jones D, Bhattacharyya N, Spirio L, Thliveris A, Robertson M, Egan S, Meuth M, White R: Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene. Cancer Res 1995, 55:1531-1539.
32. INK4. Science 1995, 267:249-252.
33. Wales MM, Biel MA, Deiry WE, Nelkin BD, Issa J-P, Cavenee WK, Kuerbitz SJ, Baylin SB: p53 Activates expression of HIC-1, a new candidate tumor suppressor gene on 17p13.3. Nat Med 1995, 1:570-577.
34. s sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995, 55:2507-2510.
35. Mueller BM, YU YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci U S A 1995, 92:205-209.
36. Kihara A, Pastan I: Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res 1995, 55:71-77.
37. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB: Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein. Cancer Res 1994, 54:4703-4709.
38. Moolten FL: Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994, 1:279-287.
39. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TKH, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca A: Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994, 5:969-978.
40. Moolten FL: Mosaicism induced by gene insertion as a means of improving chemotherapeutic selectivity. Crit Rev Immunol 1990, 10:203-233.
41. Mullen CA, Kilstrup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5 fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992, 89:33-37.
42. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G: 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995, 154:5302-5312.
43. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, Parker WB: Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994, 1:233-238. The bacterial DEOD gene was used to catalyze the conversion of a normally nontoxic adenine analogue. A bystander killing effect was reported in colon carcinoma cells expressing DeoD and treated with the 6-methylpurine substrate.
44. Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ: Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 1994, 54:5171-5177. The bacterial carboxypeptidase G2 enzyme was targeted to malignant breast cells overexpressing erbB-2 via a rat monoclonal antibody against the external domain of the human erbB-2 receptor. The authors used a mustard alkylating agent as a prodrug, and a dose-dependent tumor stasis or regression was reported.
45. Colombo BM, Benedetti S, Ottolenghi S, Mora M, Polio B, Poli G, Finocchiaro G: The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995, 6:763-772.
46. Izquierdo M, Cortes M, de Felipe P, Martin V, Diez-Guerra J, Talavera A, Perez-Higueras A: Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 1995, 2:66-69.
47. Jia WW-G, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F: Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 1994, 86:1209-1215.
48. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH: The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994, 81:256-260.
49. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994, 54:6228-6234. This paper provides evidence that an immune component may play a role in the bystander effect seen in murine melanoma cells expressing the HSVTK gene from the tyrosinase promoter in a retroviral construct.
50. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994, 54:5258-5261.
51. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994, 116:205-213.
52. Manome Y, Abe M, Hagen MF, Fine HA, Kufe DW: Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res 1994, 54:5408-5413. Enhanced sensitivity of breast cancer cells to ganciclovir was achieved via transcriptional regulation of HSVTK expression with an enhancer sequence from the breast specific DF3 promoter. Evidence for a bystander effect was also shown.
53. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, Litzky LA, Kaiser LR, Albelda SM: Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995, 13:7-16.
54. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen S-H, Woo SLC, Roop DR: Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 1995, 104:313-317.
55. O'Malley BW Jr, Chen S-H, Schwartz MR, Woo SLC: Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995, 55:1080-1085.
56. Culver KW, Ram Z, Walbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 1992, 256:1550-1552.
57. Bi LW, Parysek LM, Warnick R, Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993, 4:725-731.
58. Hwu P: The Gene Therapy of Cancer. In Principles and Practice of Oncology. Edited by VT DeVita Jr, S Hellman, SA Rosenberg. Philadelphia: JB Lipincott; 1995: 1-13.
59. Bubenik J: Cytokine gene-modified vaccines for immunotherapy of cancer [review]. Int J Oncol 1995, 6:45-49.
60. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, Pugh TD, Ershler WB, Yang N-S: In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci U S A 1995, 92:2889-2893. This paper describes an in vivo cancer gene therapy approach to introduce cytokine genes into tumor-bearing animals by Accell (Agracetus) particle-mediated gene transfer. This "gene gun" was reported to achieve up to 100-fold higher transgene expression.
61. Hathorn RW, Tso C-L, Kaboo R, Pang S, Figlin R, Sawyers C, deKernion JB, Belldegrun A: In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interteukin-2 and/or interferon-alpha gene transfer. Cancer 1994, 74:1904-1911.
62. Han SK, Brody SL, Crystal RG: Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-α cDNA. Am J Respir Cell Mol Biol 1994, 11:270-278.
63. Isobe K-I, Fan Z-H, Emi N, Nakashima I: Gene transfer of TNF receptor for treatment of cancer by TNF. Biochem Biophys Res Commun 1994, 202:1538-1542.
64. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE: Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 1995, 6:591-601.
65. Arienti F, Sule-Suso J, Melani C, Maccalli C, Belli F, Illeni MT, Anichini A, Cascinelli N, Colombo MP, Parmiani G: Interleukin-2 gene transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum Gene Ther 1994, 5:1139-1150.
66. Walsh P, Dorner A, Duke RC, Su L-J, Glode LM: Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer Inst 1995, 87:809-816. This paper reports that genetic induction of murine melanoma cells to express macrophage colony-stimulating factor elicited an efficient antitumor response in vivo and prolonged survival.
67. Elkins KL, Ennist DL, Winegar RK, Weir JP: In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum Gene Ther 1994, 5:809-820.
68. Wei MX, Tamiya T, Hurford RK Jr, Boviatsis EJ, Tepper RI, Chiocca EA: Enhancement of Interleukin-4 mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther 1995, 6:437-443.
69. Dougherty GJ, Thacker JD, Lavey RS, Belldegrun A, McBride WH: Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo. Cancer Immunol Immunother 1994, 38:339-345.
70. Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994, 54:5552-5555.
71. Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994, 54:6477-6483.
72. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, Curiel DT: A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995, 2:59-65. A plasmid encoding the cDNA for CEA functioned as a polynucleotide vaccine to elicit humor and cellular immune responses and protected against syngenic CEA-expressing colon cancer cells.
73. Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, Benjamin R, Lu D, Curiel DT: Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995, 55:1397-1400. This paper reports on the feasibility of using mRNA transcripts for polynucleotide vaccination strategies.